Despite modest impacts on amyloid pathology, bexarotene did indeed engage the LXR target gene Abca1, resulting in elevated mRNA and protein levels in the brain (Fig. 4a, top and bottom). This evidence concerns the gene ABCA1 and amyloidosis.